NOTICE OF INTENT TO ADOPT AND AMEND ADMINISTRATIVE RULES

TAKE NOTICE that the North Dakota State Board of Pharmacy will hold a public hearing to address proposed amendments to N.D Admin. Code 61-02-01-03 Pharmaceutical Compounding Standards and 61-02-07.1 - Pharmacy Technicians Tasks and 61-08-01-10 Counseling Services [of Out-of-State Pharmacies] and a proposed new section in N.D. Admin. Code 61-04-12 Patient Consultation Requirements at **4:00PM on Saturday, April 30, 2016, at the annual NDPhA Convention held at the Radisson Hotel- New York New York - 605 East Broadway, Bismarck, ND**.

<u>61-02-01-03 Pharmaceutical Compounding Standards</u> - modifies standards consistent with federal guidelines for compounding of pharmaceutical products.

<u>61-02-07.1 - Pharmacy Technicians Tasks</u> - allows a Registered Pharmacy Technician to assess a patient receiving a refilled prescription for consultation with the pharmacist.

<u>61-04-12 Patient Consultation Requirements</u> – establishes patient consultation parameters for patients receiving an out-patient prescription to assure proper treatment by educating the patient or their representative on their prescription.

<u>61-08-01-10 Counseling Services</u> – requires an Out-of-State Pharmacy to counsel consistent with the same expectations of an in-state pharmacy, to assure proper treatment by educating the patient or their representative on their prescription.

The proposed amendments and new sections are expected to have an impact on the regulated community in excess of \$50,000. A copy of the proposed rules are available at www.nodakpharmacy.com or may be obtained by writing the North Dakota State Board of Pharmacy, calling (701) 328-9535 or by email ndboph2@btinet.net. Also, written comments may be submitted to 1906 East Broadway, Bismarck, ND 58501 until May 20th 2016. If you plan to attend the public hearing and will need special facilities or assistance relating to a disability, please contact the North Dakota State Board of Pharmacy at the above telephone number or address at least 14 days prior to the public hearing.

Dated this 18th day of March, 2016.

Mark J. Hardy, PharmD Executive Director